uncategorized

Distinct mutations in the CACNA1A gene — which contains instructions for producing a subunit of CaV2.1, a calcium channel key to nerve cell communication — are associated with Lennox-Gastaut syndrome (LGS), a study suggests. Assessing the impact of these different CACNA1A mutations in CaV2.1’s function and location may…

The U.S. Food and Drug Administration (FDA) approved Neurelis’ Valtoco (diazepam nasal spray) as a rescue treatment for seizure clusters in people with epilepsy ages 6 and older. “Cluster or acute repetitive seizures are challenging to treat and highly disruptive in the lives of people with epilepsy,”…

Using Fycompa (perampanel) — an approved anti-seizure treatment for certain types of epilepsy — as an add-on therapy significantly reduced the frequency of seizures in adults with Lennox-Gastaut syndrome (LGS), a recent study shows. Based on these data, researchers suggested that Fycompa be considered for LGS patients with…

Combining cannabidiol (CBD) with clobazam — a well-known treatment for childhood epilepsies like Lennox‑Gastaut syndrome (LGS) — leads to greater anti-seizure effects, but only when given at its therapeutic dose, a preclinical study shows. These findings, which suggest that CDB has its own anti-seizure properties, may bring clarity to…